Wechselwirkungen · Sivextro
Sivextro 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-130234 · Präparat HOS-096879
Breast cancer resistance protein transporter inhibition In a clinical study comparing the single dose (10 mg) pharmacokinetics of rosuvastatin (Breast Cancer Resistant Protein [BCRP] substrate, see section 5.2) alone or in combination with tedizolid phosphate (once-daily 200 mg oral dose), rosuvastatin AUC and Cmax increased by approximately 70% and 55%, respectively, when co-administered with tedizolid phosphate. Therefore, orally administered tedizolid phosphate can result in inhibition of BCRP at the intestinal level. If possible, an interruption of the co- administered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate, pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of treatment with oral tedizolid phosphate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) rosuvastatin (HOS-086307) imatinib (HOS-110212) lapatinib (HOS-122565) topotecan (HOS-086047) methotrexate (HOS-087522) tedizolid phosphate (HOS-130230) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage 9edcbf20c0dd1a9a2297e953e0bad5b473fc9fbc3573e6faff13cba7d926488e · Zeichen 69–866 im Abschnitt